نتائج البحث - Law, Steven
- يعرض 1 - 8 نتائج من 8
-
1
-
2
Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplan... حسب Ainley, Louise, Law, Steven, Heptinstall, Lauren, Rodriguez-Justo, Manuel, Thomson, Kirsty, Pepper, Ruth J.
منشور في 2020نص -
3
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis حسب Ravichandran, Sriram, Law, Steven, Mahmood, Shameem, Wisniowski, Brenden, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Hawkins, Philip N., Wechalekar, Ashutosh D.
منشور في 2022نص -
4
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib حسب Ravichandran, Sriram, Cohen, Oliver C., Law, Steven, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Sachchithanantham, Sajitha, Mahmood, Shameem, Hawkins, Philip N., Wechalekar, Ashutosh D.
منشور في 2021نص -
5
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis حسب Cohen, Oliver C., Law, Steven, Lachmann, Helen J., Sharpley, Faye, Ravichandran, Sriram, Mahmood, Shameem, Sachchithanantham, Sajitha, Whelan, Carol J., De Azcona Naharro, Ana Martinez, Fontana, Marianna, Hawkins, Philip N., Gillmore, Julian D., Wechalekar, Ashutosh D.
منشور في 2020نص -
6
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage حسب Law, Steven, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C., Ravichandran, Sriram, Gilbertson, Janet A., Rowczenio, Dorota, Wechalekar, Ashutosh, Martinez‐Naharro, Ana, Lachmann, Helen J., Whelan, Carol J., Hutt, David F., Hawkins, Philip N., Fontana, Marianna, Gillmore, Julian D.
منشور في 2020نص -
7
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy حسب Law, Steven, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C, Ravichandran, Sriram, Gilbertson, Janet A, Rowczenio, Dorota, Wechalekar, Ashutosh D, Martinez-Naharro, Ana, Lachmann, Helen J, Whelan, Carol J, Hutt, David F, Hawkins, Philip N, Fontana, Marianna, Gillmore, Julian D
منشور في 2022نص -
8
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis حسب Law, Steven, Bezard, Melanie, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C, Ravichandran, Sriram, Ogunbiyi, Olabisi, Kharoubi, Mounira, Ganeshananthan, Sashiananthan, Ganeshananthan, Sharmananthan, Gilbertson, Janet A, Rowczenio, Dorota, Wechalekar, Ashutosh, Martinez-Naharro, Ana, Lachmann, Helen J, Whelan, Carol J, Hutt, David F, Hawkins, Philip N, Damy, Thibaud, Fontana, Marianna, Gillmore, Julian D
منشور في 2022نص